Autolus Therapeutics plc
AUTL
$2.03
-$0.08-3.79%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.69M | 26.22M | 24.29M | 21.19M | 20.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.69M | 26.22M | 24.29M | 21.19M | 20.92M |
| Cost of Revenue | 48.37M | 45.78M | 54.29M | 56.54M | 51.88M |
| Gross Profit | -2.68M | -19.56M | -30.00M | -35.34M | -30.95M |
| SG&A Expenses | 41.16M | 39.95M | 42.12M | 36.28M | 30.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.53M | 85.73M | 96.41M | 92.82M | 82.14M |
| Operating Income | -43.84M | -59.51M | -72.12M | -71.62M | -61.22M |
| Income Before Tax | -38.65M | -70.74M | -91.52M | -78.59M | -47.52M |
| Income Tax Expenses | 465.00K | 863.00K | -1.18M | 532.00K | 397.00K |
| Earnings from Continuing Operations | -39.11M | -71.60M | -90.33M | -79.12M | -47.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.11M | -71.60M | -90.33M | -79.12M | -47.92M |
| EBIT | -43.84M | -59.51M | -72.12M | -71.62M | -61.22M |
| EBITDA | -41.19M | -56.81M | -69.49M | -69.08M | -58.85M |
| EPS Basic | -0.15 | -0.27 | -0.34 | -0.30 | -0.18 |
| Normalized Basic EPS | -0.09 | -0.17 | -0.21 | -0.18 | -0.11 |
| EPS Diluted | -0.15 | -0.27 | -0.34 | -0.30 | -0.18 |
| Normalized Diluted EPS | -0.09 | -0.17 | -0.21 | -0.18 | -0.11 |
| Average Basic Shares Outstanding | 266.16M | 266.14M | 266.14M | 266.14M | 266.14M |
| Average Diluted Shares Outstanding | 266.16M | 266.14M | 266.14M | 266.14M | 266.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |